PFG
CLDX icon

Pacific Financial Group’s Celldex Therapeutics CLDX Stock Holding History

Pacific Financial Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-33
Closed -$9K – 71
2014
Q4 		$9K Buy
+33
New +$8.2K ﹤0.01% 160

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacific Financial Group's CLDX Position: Q1 2015 in Review

Pacific Financial Group sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 33 shares — an estimated $9K sold.

Pacific Financial Group first reported a position in CLDX in Q4 2014 and held it in 1 quarter. The position peaked at $9K in Q4 2014. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

  • Pacific Financial Group reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Pacific Financial Group sold 33 Celldex Therapeutics shares in Q1 2015, an estimated $9K.
  • Pacific Financial Group first reported a position in Celldex Therapeutics in Q4 2014 and held it in 1 quarter.
  • Pacific Financial Group's Celldex Therapeutics position peaked at $9K in Q4 2014.
  • 193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on Pacific Financial Group's 13F filing for Q1 2015, filed 27 Apr 2015.